
The Immune Deficiency Foundation (IDF) improves the diagnosis, treatment, and quality of life for every person affected by PI. The IDF fosters a community that is connected, engaged, and empowered through advocacy, education, and research.
For Healthcare Professionals
Hypothetical patient.
Copay assistance is available for eligible patients on QIVIGY covered under both pharmacy and medical benefits.
Hypothetical patient.
Copay assistance is available for eligible patients on QIVIGY covered under both pharmacy and medical benefits.
The program covers the copay, deductible, and/or co-insurance associated with the cost of QIVIGY only. The program does not cover costs associated with administration or supplies.
A dedicated team of reimbursement specialists are ready to provide support
888-262-8040
reimbursementsupport@medmonk.com
The following list of patient advocacy groups can help support you on your journey with PI.

The Immune Deficiency Foundation (IDF) improves the diagnosis, treatment, and quality of life for every person affected by PI. The IDF fosters a community that is connected, engaged, and empowered through advocacy, education, and research.

The Jeffrey Modell Foundation is a global nonprofit dedicated to early diagnosis, meaningful treatments and, ultimately, cures through basic and clinical research, physician and patient education, public awareness, government advocacy, patient support, newborn screening, and genetic sequencing.

The International Patient Organisation for Primary Immunodeficiencies (IPOPI) is an international nonprofit organization and the leading worldwide advocate for people with PI.

The Immunoglobulin National Society (IgNS) is a professional organization dedicated to the advancement of Ig therapy practice across clinical indications and areas of practice.
Ig, immunoglobulin; PI, primary immunodeficiency.
QIVIGY® (immune globulin intravenous, human-kthm) is a 10% immune globulin (Ig) liquid indicated for the treatment of adults with primary humoral immunodeficiency.
See full prescribing information for complete boxed warning.
QIVIGY is contraindicated in patients who have had an anaphylactic or severe systemic reaction to the administration of human immune globulin and in IgA deficient patients with antibodies against IgA and history of hypersensitivity.
Severe hypersensitivity reactions, including anaphylaxis, may occur. In case of hypersensitivity, discontinue QIVIGY infusion and manage as appropriate.
Hyperproteinemia, hyperviscosity, and hyponatremia may occur in patients receiving IGIV treatment, including QIVIGY.
Aseptic meningitis syndrome may occur in patients receiving IGIV treatment, especially with high doses or rapid infusion.
Hemolysis can develop subsequent to IGIV treatment. Monitor patients for hemolysis.
Transfusion-related acute lung injury: Monitor patients for pulmonary adverse reactions.
Transmissible infectious agents: QIVIGY is made from human plasma and may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.
Interference with laboratory tests: After infusion of Ig, transitory rise of passively transferred antibodies may yield positive serological results, with potential for misleading interpretation.
The most common adverse reactions occurring in ≥5% of patients treated were headache, fatigue, infusion-related reaction, Coombs direct test positive, nausea, sinusitis, dizziness, and diarrhea.
To report SUSPECTED ADVERSE REACTIONS, contact Kedrion Biopharma Inc. at 1-855-3KDRION (1-855-353-7466) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see full Prescribing Information for complete prescribing details, including Boxed Warning.